Novo Nordisk Wegovy pill patients lost 6.2 percent of body weight in three months, data show
Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2 per cent of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Study participants, who started taking the pill between January 5 and February 7, 2026, lost an average of 6.3 kg (13.9 pounds) from a baseline weight of 103.0 kg (227 pounds), Novo said. About three-fifths lost at least 5 per cent of their weight, and roughly one in six lost at least 10 per cent.
The analysis covered 5,872 adults on the Ro telehealth platform who had never taken a weight-loss drug and who stayed on the pill for the full three months.
Novo’s Chief Scientific Officer Martin Holst Lange said in an interview that the real-world data was encouraging as it broadly replicated the findings of 5.5 per cent weight loss at 12 weeks seen in Novo’s late-stage trial for the pill.
Oral Wegovy — known chemically as semaglutide — led to about a 14 per cent reduction in body weight over 64 weeks, while Eli Lilly’s obesity pill Foundayo led to about an 11 per cent reduction over 72 weeks, separate studies have shown.
